ClinicalTrials.gg
RecruitingNCT07518329SAPPHIREUpdated Oct 29, 2026

Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.

A Phase 1 interventional study of ALA-101 in Non Hodgkin Lymphoma (NHL) and Leukaemia, sponsored by Arovella Therapeutics Ltd. Recruiting at 5 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Arovella Therapeutics Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 29, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 151 studies in Lymphoma, Non-Hodgkin with a site in Australia — 31 open to participants now, 64 under way, 16 of them phase 3. Lymphoma, Non-Hodgkin · Australia.

Planned enrollment
112th of 147
46 · median 137
Started
2026
with 6 others
Phase 1
50 of 151
14 open now
Primary completion
2030-03
later than 57 of 63 live
Registered
149th of 151
by date

Among the 151 studies in Lymphoma, Non-Hodgkin with a site in Australia, this one is the 112th largest by planned enrollment of the 147 interventional ones that give a count, is one of 7 that started in 2026, is one of 50 in phase 1, reaches primary completion later than 57 of the 63 other live ones, and was the 149th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

31 of the 151 studies in Lymphoma, Non-Hodgkin with a site in Australia are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Lymphoma, Non-Hodgkin with a site in Australia, or all of them as a file.
02

Study summary

Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101

Read the detailed description

This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ALA-101, an allogeneic, off-the-shelf CD19-directed CAR-iNKT cell therapy, in patients with CD19-positive non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and hairy cell leukemia (HCL).

The dose-escalation phase will assess safety and determine the maximum tolerated dose (MTD). The dose-expansion/backfill phase will further evaluate safety and preliminary efficacy and establish the recommended Phase 2 dose (RP2D).

Study participation includes screening, lymphodepletion, treatment, and follow-up periods. An end-of-study visit will occur at Month 24, after which participants will enter a long-term follow-up study.

03

Conditions studied

  • Non Hodgkin Lymphoma (NHL)
  • Leukaemia

Keywords

  • C19+
  • Lymphoma
  • Leukemia
  • CART T CELL
  • iNKT
  • CAR iNKT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years old
  • Confirmed Diagnoses of Confirmed diagnosis of CD19+ non-Hodgkins lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphatic Leukemia or Hairy Cell Leukemia
  • greater than 3 months
  • Adequate Hepatic and Renal Function
  • Adequate Bone Marrow Function
  • Adequate Vales
  • Agree to use appropriate to avoid becoming pregnant for up to 12 months post treatment and agree not to donate sperm or ova for 12 months post treatment

Exclusion criteria

Exclusion Criteria:

  • Prior anti-CD1d monoclonal antibody treatment
  • Prior stem cell transplant except where the participant is greater than 100 days and does not have (uncontrolled)
  • Prior Organ Transplant
  • Previous in last 3 years that's active or been treated.
  • Current central nervous system involvement by lymphoma or leukaemia
  • Evidence of Cardiac Dysfunction
  • Active disease requiring systemic therapy within the past 6 months.
  • Known active , or (HIV) infection.
  • History of Graft Vs Host Disease Grade 2 to 4
  • No active Graft Vs Host Disease following a minimum of 3 months withdrawal from all Graft Vs Host Disease treatments
  • Must not have received systemic anti-cancer therapy for the underlying malignancy within 6 weeks prior to the start of conditioning chemotherapy on Day -6.
  • Participants that have received autologous or allogenic CAR-T cell therapy within 3 months prior to commencing screening.
  • Use of systemic within 15 days of commencement of conditioning chemotherapy on Day -6 or other immunosuppressive drugs within 30 days
  • Recent major surgery (within 4 weeks prior to commencement of conditioning chemotherapy on Day -6) or planned major surgery within 8 weeks following ALA-101 infusion on Day 1.
  • Active infection requiring intravenous antibiotic, antifungal, or antiviral medication or hospital admission within 10 days prior to commencement of conditioning chemotherapy on Day -6
  • Severe (e.g., severe , severe Parkinson's disease) or poorly controlled (e.g., hypertension, diabetes, active inflammatory bowel disease) medical condition.
  • Vaccinated with a within 28 days prior to commencement of conditioning chemotherapy on Day -6 or planned live vaccination within 6 months following ALA-101 infusion.

Additional criteria apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Treatment Dose Level 1

    50 × 10\^6 CAR+ iNKT cells (starting dose level)

    Drug: ALA-101

  • Experimental
    Treatment Dose Level -1

    Dose level -1: 20 × 10\^6 CAR+ iNKT cells (in case of DLTs on Dose Level 1)

    Drug: ALA-101

  • Experimental
    Treatment Dose Level 2

    150 × 10\^6 CAR+ iNKT cells

    Drug: ALA-101

  • Experimental
    Treatment Dose Level 3

    300 × 10\^6 CAR+ iNKT cells

    Drug: ALA-101

  • Experimental
    Treatment Dose Level 4

    500 × 10\^6 CAR+ iNKT cells

    Drug: ALA-101

Interventions

  • DrugALA-101

    Single IV infusion of ALA-101 post chemotherapy conditioning with Fludarabine and Cyclophosphamide

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of ALA-101 in adult participants with CD19+ NonHodgkin Lymphoma (NHL) and CD19+ leukemia

    Incidence, type and severity of treatment emergent and treatment-related adverse events (AEs) and Incidence and nature of dose-limiting toxicities (DLTs)

    Time frame: 2 years

Secondary outcomes

  1. To determine the maximum tolerated dose (MTD) and appropriate recommended Phase 2 dose (RP2D) for progression into next stages of clinical studies in adult participants with CD19+ NHL and/or CD19+ leukemia.

    Determination of MTD using isotonic regression and Determination of RP2D considering both the MTD and totality of safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) data collected.

    Time frame: 2 years

  2. To evaluate the preliminary efficacy of ALA-101 in adult participants with CD19+ NHL and/or CD19+ leukemia

    Overall Response Rate (ORR)

    Time frame: 2 years

  3. To characterize the PK profile of ALA-101

    Levels of ALA-101 in blood will be assessed using digital polymerase chain reaction (dPCR). Where data permits, endpoints to be evaluated include (but are not limited to): o Maximum observed Peak Plasma Concentration (Cmax)

    Time frame: 1 year

  4. To evaluate the immunogenicity of ALA-101

    Incidence of anti-ALA-101 antibodies following ALA-101 administration.

    Time frame: 2 years

  5. To characterize the PK profile of ALA-101

    Levels of ALA-101 in blood will be assessed using digital polymerase chain reaction (dPCR). Where data permits, endpoints to be evaluated include (but are not limited to): Area under the plasma concentration versus time curve (AUC)

    Time frame: 1 Year

07

Study locations

1 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2030, 41 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 71. This study's planned 41 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Apr 8, 2026
StartActual
Oct 19, 2026was Aug 2026
Primary completionEst.
Mar 31, 2030
CompletionEst.
Aug 30, 2030
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
5 sites changed recruiting status (4 now not yet recruiting, 1 now recruiting)
Show 5 sites
  • St. Vincent's Hospital · Sydney, Australiano status→Not yet recruiting
  • Mater Misericordiae Ltd (MML) · Brisbane, Australiano status→Not yet recruiting
  • Royal Adelaide Hospital · Adelaide, Australiano status→Not yet recruiting
  • The Alfred Hospital · Melbourne, Australiano status→Recruiting
  • Epworth HealthCare · Richmond, Australiano status→Not yet recruiting
Oct 29, 2026
Start date
Aug 20, 2026→Oct 19, 2026 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    5 sites changed recruiting status (4 now not yet recruiting, 1 now recruiting)
    Show 5 sites
    • St. Vincent's Hospital · Sydney, Australiano status→Not yet recruiting
    • Mater Misericordiae Ltd (MML) · Brisbane, Australiano status→Not yet recruiting
    • Royal Adelaide Hospital · Adelaide, Australiano status→Not yet recruiting
    • The Alfred Hospital · Melbourne, Australiano status→Recruiting
    • Epworth HealthCare · Richmond, Australiano status→Not yet recruiting
    Start date Aug 20, 2026→Oct 19, 2026 (now actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07518329
Lead sponsor
Arovella Therapeutics Ltd
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Oct 19, 2026
Primary completion
Mar 31, 2030 (estimated)
Completion
Aug 30, 2030 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion